Weekly Irinotecan in Patients with Metastatic Colorectal Cancer Failing 5-Fluorouracil-Based Chemotherapy: Efficacy and Prognostic Factors

Karaoğlu, Aziz; Yalçın, Şuayib; Tekuzman, Gülten; Kars, Ayse; Çeli̇k, İsmai̇l; Güler, Nilüfer; Özışık, Yavuz; Türker, Alev; Barışta, İbrahim; Güllü, İbrahi̇m

doi:10.1177/030089160308900207

Cited by 5 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In seven study samples, irinotecan was administered weekly for 4 consecutive weeks, using a dose of 125 mg/m 2 , followed by a 2-week rest period [15,16,18,22,26,35,37]. The remaining 14 study samples used other regimens, including dose variations on the 3-weekly schedule [21,30] and the weekly schedule [14,18,28,32]. Furthermore, there were changes in the frequency of the schedule to weekly doses without a rest period [27], or to a 2-weekly schedule [34,35,36], and changes in the dose by escalation [5,31], or adapting the dose according to patient characteristics [5,24,34].…”

Section: Phase II Studies Description Of Studiesmentioning

confidence: 99%

Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer

Oostendorp

Stalmeier²,

Jong

et al. 2010

Anti-Cancer Drugs

View full text Add to dashboard Cite

This study was performed to obtain a comprehensive overview of the benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. The literature was systematically reviewed to identify phase II and phase III trials that investigated the effect of second-line monotherapy with irinotecan. Thirty studies were included in this review: 25 phase II studies including 32 samples and five phase III studies including six samples. A disease control rate of greater than or equal to 50% was found in 23 out of 32 phase II samples, and one out of two phase III samples that reported disease control rate. Median time to progression was 2.7-6.0 months in phase II samples and 3.0-4.3 months in phase III samples. Median overall survival ranged from 6.6 to 16.1 months in phase II samples and 9.1-10.8 months in phase III samples. The most important severe adverse event in both phase II and phase III trials was diarrhea (5-39 and 15-36%, respectively), followed by nausea (1-24 and 5-14%), vomiting (2-22 and 6-14%), and asthenia (0-31 and 4-21%). Treatment-related mortality was 0-2% in phase II samples and 0-5% in phase III samples. Quality-of-life scores in phase II studies were associated with tumor response. In phase III studies, the quality of life while on treatment with irinotecan was similar to that of 5-fluorouracil, but better than supportive care alone. The quality of life on the weekly schedule was similar to the 3-weekly schedule. This study provides a comprehensive overview of the benefits and risks of second-line irinotecan. In general, second-line treatment with irinotecan is beneficial to patients.

show abstract

Section: Phase II Studies Description Of Studiesmentioning

confidence: 99%

Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer

Oostendorp

Stalmeier²,

Jong

et al. 2010

Anti-Cancer Drugs

View full text Add to dashboard Cite

show abstract

Biweekly Irinotecan Plus Bolus 5-Fluorouracil and Folinic Acid in Patients with Advanced Stage Colorectal Cancer

Yalçın

Öksüzoğlu

Tekuzman

et al. 2003

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Single-Agent Irinotecan as Second-Line Weekly Chemotherapy in Elderly Patients with Advanced Colorectal Cancer

Rosati¹,

Cordio

2006

Tumori

View full text Add to dashboard Cite

show abstract

Weekly Irinotecan in Patients with Metastatic Colorectal Cancer Failing 5-Fluorouracil-Based Chemotherapy: Efficacy and Prognostic Factors

Abstract: We concluded that weekly irinotecan at the dose of 100 mg/m2 is an effective and tolerable treatment option, with a 50% disease control rate, for patients with colorectal cancer failing previous 5-fluorouracil-based chemotherapy.

Cited by 5 publications

References 20 publications

Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer

Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer

Biweekly Irinotecan Plus Bolus 5-Fluorouracil and Folinic Acid in Patients with Advanced Stage Colorectal Cancer

Single-Agent Irinotecan as Second-Line Weekly Chemotherapy in Elderly Patients with Advanced Colorectal Cancer

Contact Info

Product

Resources

About